Introduction

The NCI-H2122 Cells — also known by the synonyms H2122, H-2122, and NCIH2122 — represent a widely used human non-small cell lung cancer (NSCLC) cell line derived from a pleural effusion of a patient with lung adenocarcinoma. Established as part of the National Cancer Institute's systematic effort to develop comprehensively annotated human cancer models, NCI-H2122 carries a homozygous KRAS G12C point mutation that makes it an indispensable tool for investigating oncogenic RAS signalling and the emerging class of KRAS-G12C-selective inhibitors. [1] Alongside this driver mutation, the line carries the co-alterations most characteristic of aggressive KRAS-mutant lung adenocarcinoma — TP53 mutation, homozygous CDKN2A/B loss, STK11/LKB1 inactivation, and a KEAP1 mutation — which makes it a clinically representative rather than a single-driver model. The cell line has been incorporated into major pan-cancer genomic and proteomic atlases, including the Cancer Cell Line Encyclopedia (CCLE) and the Cancer Dependency Map project, further cementing its importance in translational oncology research. Its well-defined mutational profile, suspension-like growth characteristics, and broad omics coverage make NCI-H2122 a cornerstone model for drug discovery, biomarker identification, and combination therapy studies in lung cancer.

Key Takeaways

• NCI-H2122 (CVCL_1531) is a human lung adenocarcinoma cell line derived from a pleural effusion metastasis and classified as NSCLC.
• The cell line carries a homozygous KRAS G12C (p.Gly12Cys) mutation, making it a premier model for KRAS-targeted therapy research.
• Two heterozygous TP53 mutations and microsatellite stability (MSS) further characterise its genomic landscape.
• NCI-H2122 additionally carries homozygous CDKN2A/B deletion, STK11/LKB1 inactivation, and a KEAP1 mutation — the classic co-mutation pattern of aggressive KRAS-driven lung adenocarcinoma.
• The line is part of multiple landmark consortia, including the CCLE, DepMap, COSMIC, the MD Anderson Cell Lines Project, and the NCI RAS program mutant KRAS cell line panel.
• Extensive omics data — encompassing genomics, transcriptomics, proteomics, and drug screening — are publicly available for this line.
• The cell line has been used to evaluate combination regimens involving KRAS inhibitors, CDK4/6 inhibitors, WEE1 inhibitors, and checkpoint kinase inhibitors.

What is NCI-H2122?

NCI-H2122 was derived in January 1989 from the pleural effusion metastasis of a 46-year-old female patient with a 30 pack-year smoking history who had been diagnosed with lung adenocarcinoma. The cell line was established by the National Cancer Institute's Navy Medical Oncology Branch as part of a systematic, Institutional Review Board-approved effort begun in 1976 to generate human cancer cell lines as biological research tools. [1] The line was subsequently catalogued in the NCI cell line database, which documents both the clinical histories of donor patients and extensive in vitro characterisation data. [2] An autologous B-lymphoblastoid line derived from the same donor, NCI-BL2122 (CVCL_2651), is also available and provides a matched normal control for genomic and authentication work.

Genomically, NCI-H2122 carries a homozygous KRAS p.Gly12Cys (c.34G>T) mutation; the homozygous status of this allele was established in the early ras and p53 mutation surveys of the NCI NSCLC panel. [3] The line additionally harbours two heterozygous TP53 mutations, p.Gln16Leu (c.47A>T) and p.Cys176Phe (c.527G>T), which were characterised by direct sequencing of a large lung adenocarcinoma cell line panel. [4] The cell line exhibits microsatellite stability (MSS). Spectral karyotyping of the NCI-H series showed that NCI-H2122 is notable for a near-diploid karyotype to which structurally abnormal chromosomes have been added, in contrast to lines whose genomes evolved through large-scale unbalanced translocation. [5] Array-based comparative genomic hybridisation subsequently provided a detailed copy number alteration map for NCI-H2122 and other NSCLC models. [6] Beyond KRAS and TP53, NCI-H2122 carries homozygous deletion of CDKN2A/B, [7] inactivation of STK11/LKB1, [8] and a KEAP1 mutation. [9] The cell line has an estimated genetic ancestry predominantly of Northern and Southern European origin (approximately 66 % and 31 % of the genome, respectively), as determined from genome-wide genotyping data. [10] It grows as moderate to large, viable, loose clusters that either loosely adhere to the flask or remain in suspension, with a reported doubling time of 27–32 hours.

Cell Culture Information

Advantages of NCI-H2122 Cells

One of the most significant strengths of NCI-H2122 is its well-defined, homozygous KRAS G12C mutation. Unlike heterozygous models, the homozygous status ensures that essentially all KRAS signalling is driven by the oncogenic allele, providing a clean and unambiguous system for evaluating KRAS-G12C-selective inhibitors such as adagrasib and sotorasib. The line is included in the NCI RAS program mutant KRAS cell line panel, the curated set of models assembled for consistent, reproducible evaluation of KRAS pathway interventions. The concurrent TP53, CDKN2A/B, STK11, and KEAP1 alterations further replicate the multi-hit genomic landscape typically found in clinical lung adenocarcinoma, enhancing translational relevance for the aggressive co-mutant subgroup.

A second major advantage is the exceptional depth of publicly available omics data accompanying this line. NCI-H2122 has been profiled across multiple CCLE iterations, contributing DNA methylation, whole-exome sequencing, RNA sequencing, microarray, reverse-phase protein array, phosphoproteomic, and drug screening data. [11] [12] [13] [14] This multi-omics backbone allows researchers to contextualise experimental findings within a rich comparative framework spanning hundreds of cancer cell lines. The availability of genome-scale shRNA loss-of-function data from Project Achilles, [15] together with the CRISPR knockout screens subsequently added to the Cancer Dependency Map portal, further enables the identification of synthetic lethal interactions in the KRAS-mutant context.

NCI-H2122 also benefits from decades of cumulative experimental validation across diverse research questions. Its responsiveness to adagrasib in preclinical settings — in contrast to adagrasib-resistant lines such as SW-1573 Cells — makes it useful for comparing sensitive versus resistant KRAS-G12C phenotypes in the same experimental design. [7] The authenticated short tandem repeat profile, catalogued in resources such as the cell line annotation framework described by Yu et al., [16] and integration into the TCLP knowledgebase with HLA type and predicted neo-epitopes, [17] further supports reproducible, high-quality experimental work.

Limitations of NCI-H2122 Cells

Like all established cancer cell lines, NCI-H2122 has undergone extensive in vitro adaptation since its derivation. Prolonged culture can introduce additional genomic alterations beyond those present in the original tumour, potentially diverging from the primary tumour biology it was intended to model. Researchers should monitor passage number carefully and verify key mutations periodically, particularly the KRAS G12C status, to ensure experimental consistency. The homozygous KRAS mutation, while advantageous for mechanistic clarity, may not fully recapitulate the heterozygous landscapes found in a substantial proportion of clinical KRAS-mutant NSCLC tumours.

The semi-suspension growth pattern of NCI-H2122 — forming loose, grape-like clusters that may adhere weakly or remain in suspension — can present practical challenges. Standard adherent-cell assays such as colony formation or certain migration platforms may require protocol adaptation. Achieving uniform cell distribution in assay wells demands careful optimisation of seeding and agitation conditions. Researchers transitioning from classical adherent NSCLC lines such as A549 Cells should anticipate these handling differences.

Importantly, NCI-H2122 is not a single-driver model. In addition to KRAS G12C it carries homozygous CDKN2A/B deletion, [7] inactivation of the STK11/LKB1 tumour suppressor, [8] and a KEAP1 mutation with attendant constitutive NRF2 pathway activity. [9] This is a strength when the research question concerns the aggressive, immunotherapy-refractory KRAS/STK11/KEAP1 co-mutant subgroup, but it is a genuine limitation elsewhere: findings attributed to KRAS G12C blockade alone may be confounded by LKB1-dependent metabolic rewiring or NRF2-mediated redox buffering, and the line cannot serve as an STK11- or KEAP1-wild-type comparator. Studies requiring such a comparator typically pair NCI-H2122 with a KEAP1-wild-type KRAS-G12C line such as NCI-H358. Investigators studying tumour microenvironment interactions should also acknowledge that monoculture in vitro systems inherently lack the stromal, immune, and vascular components present in vivo, necessitating complementary animal or organoid models for comprehensive preclinical evaluation.

View full specifications and order

Applications

KRAS-G12C Targeted Therapy and Combination Strategies

NCI-H2122 has become a central model for evaluating the therapeutic potential of KRAS-G12C-selective inhibitors and their rational combinations. A 2025 study by Migliarese et al. used NCI-H2122 as an adagrasib-responsive NSCLC brain metastasis model, pairing it with adagrasib-resistant SW-1573 Cells to investigate how homozygous CDKN2A loss modifies therapeutic response. [7] The combination of adagrasib and the brain-penetrant CDK4/6 inhibitor abemaciclib was found to be slightly synergistic in NCI-H2122 cells; in the orthotopic H2122 brain metastasis model, adagrasib monotherapy and the combination prolonged survival comparably, whereas in the resistant SW1573 model only the combination extended survival. [7]

Research into WEE1 inhibition as a combination partner for KRAS-G12C blockade has also prominently featured NCI-H2122. The selective WEE1 inhibitor azenosertib demonstrated synergistic antitumour activity with KRAS-G12C inhibitors across a panel of NSCLC cell lines including NCI-H2122, with NCI-H2122 serving as the principal model for the pharmacodynamic biomarker analysis of replication stress, DNA damage, and apoptosis. [18] These findings supported the concept that replication stress induced by WEE1 inhibition may sensitise KRAS-G12C-mutant tumours to targeted KRAS blockade, positioning this combination as a promising clinical strategy. A separate study exploring the MYBL2-RRM2 axis identified synergy between the WEE1 inhibitor adavosertib and the KRAS-G12C inhibitor sotorasib, using NCI-H2122 as a key in vitro and xenograft test system. [19]

The epithelial-mesenchymal transition (EMT) status of KRAS-mutant NSCLC cells has emerged as a critical determinant of combination therapy response. A study by Yoshimura et al. examining the combination of avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor) across nine KRAS-mutated NSCLC lines found NCI-H2122, NCI-H358, and NCI-H441 to be the three lines with clear synergy (combination index < 0.7), and showed that the combined effect tracked with an epithelial rather than mesenchymal phenotype — independent of phosphorylated FAK levels or whether the KRAS mutation was G12C. [20] These findings highlight NCI-H2122 as a valuable model for dissecting context-dependent combination responses. A further study modelled relapse on adagrasib in NCI-H2122 xenografts in vivo, switching after 14 days to the pan-RAS(ON) inhibitor RMC-6236 with or without the farnesyl transferase inhibitor darlifarnib (KO-2806); switching inhibitor class alone produced only tumour stasis, whereas the addition of KO-2806 elicited significant regressions. [21]

Checkpoint Kinase Inhibition and DNA Damage Response

NCI-H2122 played a pivotal role in establishing the preclinical rationale for combining checkpoint kinase 1 (CHK1) inhibition with standard-of-care chemotherapy in NSCLC. Calvo et al. used NCI-H2122 and NCI-H441 NSCLC cell lines in in vitro and in vivo models to evaluate LY2603618, a selective CHK1 inhibitor, in combination with pemetrexed. [22] Combined treatment arrested DNA synthesis after initiation of S phase, and mice bearing NCI-H2122 or NCI-H441 xenografts showed significantly increased tumour growth inhibition with the combination. These preclinical data informed a seamless phase I/II clinical study in which LY2603618 was escalated on a backbone of pemetrexed and cisplatin in patients with advanced cancer. [22]

This work illustrated the translational value of NCI-H2122 as a model that bridges laboratory findings and early-phase clinical investigation. The ability of CHK1 inhibition to interfere with S-phase progression and sensitise NSCLC cells to nucleoside antimetabolites was demonstrated using this line, contributing to broader understanding of DNA damage response pathways as therapeutic targets in KRAS-mutant lung adenocarcinoma.

Oncogenic Signalling Pathways in NSCLC

NCI-H2122 has contributed substantially to understanding how oncogenic KRAS drives downstream signalling networks. A landmark study by Heasley et al. demonstrated that NSCLC lines harbouring oncogenic Ki-Ras mutations — H460, A549, and H2122 — synthesised high levels of prostaglandin E2 (PGE2) compared with NSCLC lines lacking Ras mutations, mediated by constitutively high expression of 85-kDa cytosolic phospholipase A2 (cPLA2) and cyclooxygenase 2 (COX-2). [23] This induction was mediated through elevated cPLA2 mRNA and promoter activation, was blocked by dominant-negative Ras constructs, and was reduced in H2122 cells by the farnesyltransferase inhibitor BZA-5B, establishing a direct mechanistic link between oncogenic RAS signalling and eicosanoid biosynthesis in NSCLC.

A multi-omics study by Balbin et al. profiled the transcriptome, proteome, and phosphoproteome of a panel of NSCLC cell lines to reconstruct targetable signalling networks associated with KRAS dependency, identifying modules centred on KRAS/MET, LCK/PAK1, and β-Catenin. [24] NCI-H2122 was included in this analysis, contributing to the network model that nominated novel combination targets in KRAS-driven NSCLC. Separately, a global phosphoproteomic survey by Rikova et al. characterised tyrosine kinase activity across 41 NSCLC cell lines and more than 150 NSCLC tumours, identifying activated kinases including EGFR and c-Met as well as novel ALK and ROS fusion proteins, with NCI-H2122 among the profiled lines. [25]

Studies on GSTO1 (glutathione S-transferase omega 1) used NCI-H2122 to model GSTO1 overexpression via cDNA constructs, demonstrating that elevated GSTO1 promoted proliferation, migration, and invasion while suppressing apoptosis in NSCLC cells through the JAK/STAT3 signalling pathway. [26] Complementary work on basic fibroblast growth factor (bFGF) signalling exploited the naturally low bFGF expression of NCI-H2122 — compared with the high-bFGF A549 Cells line — to establish a controlled comparison showing that bFGF blockade suppressed A549 growth but not NCI-H2122 growth, while paradoxically enhancing A549 invasion through the AKT/MMP-2/VEGF axis. [27]

Pan-Cancer Genomic and Proteomic Profiling

NCI-H2122 has been a consistent contributor to large-scale cancer genomics initiatives. Genome-wide allelotyping studies identified major tumour suppressor loci in lung cancer, with NCI-H2122 included as part of the NSCLC panel revealing recurrent regions of loss of heterozygosity. [28] Blanco et al. assembled a comprehensive gene-alteration profile for 88 lung cancer cell lines, confirming that nearly all lines — including NCI-H2122 — feature inactivation at TP53 and CDKN2A or RB1, and documenting the mutually exclusive occurrence of KRAS and EGFR mutations. [29] A Nature study by Bignell et al. catalogued 2,428 somatic homozygous deletions across 746 cancer cell lines, with NCI-H2122 contributing to analyses identifying structural deletion signatures over recessive cancer genes and fragile sites. [30]

Large-scale proteomic profiling has further enhanced the characterisation of NCI-H2122. Reverse-phase protein array data from Li et al. measured expression levels of approximately 230 cancer-related proteins across more than 650 cell lines, demonstrating that protein and phosphoprotein data provide drug sensitivity predictions not available from mRNA alone. [31] Quantitative mass spectrometry profiling of the CCLE by Nusinow et al. expanded this further, quantifying thousands of proteins and revealing pathway correlations absent from RNA data. [13] The pan-cancer proteomic map by Gonçalves et al., covering 949 cell lines, integrated multi-omics with drug response and CRISPR essentiality screens to identify protein biomarkers of cancer vulnerabilities, with NCI-H2122 contributing to the lung adenocarcinoma subset. [14]

Transcriptomic analyses have been equally broad. Klijn et al. performed RNA sequencing and SNP array analysis of 675 cancer cell lines, cataloguing gene fusions and enabling pathway-based drug response predictions. [32] The TCLP knowledgebase integrated HLA type, predicted neo-epitopes, expressed viruses, and gene expression for over 1,000 cell lines including NCI-H2122. [17] A pharmacogenomics landscape study by Iorio et al. mapped cancer-driven alterations from 11,289 tumours onto 1,001 annotated cell lines and correlated them with sensitivity to 265 drugs, directly informing therapeutic hypotheses for KRAS-mutant NSCLC. [33] A chemistry-first drug discovery study by McMillan et al. profiled a 200,000-compound library across more than 100 lung cancer models to identify chemical-genetic associations, including a GLUT8-dependent serine biosynthesis vulnerability specific to KRAS/KEAP1 double mutants — the oncogenotype represented by NCI-H2122. [34]

Novel Drug Delivery and Therapeutic Antibody Studies

NCI-H2122 has been employed in studies evaluating novel therapeutic modalities beyond small molecules. Yada et al. investigated CS-1008, a humanised agonistic anti-death receptor 5 (DR5) antibody, and demonstrated that NCI-H2122 expresses DR5 and that its growth is inhibited by CS-1008 in vitro under antibody cross-linking conditions. [35] In vivo, athymic nude mice inoculated with NCI-H2122 were used to evaluate antitumour efficacy, and CS-1008 combined with docetaxel produced enhanced antitumour activity in this model. Notably, and unlike TRAIL, CS-1008 did not induce cell death in human primary hepatocytes — a critical safety finding from these studies.

In the emerging field of targeted nanoparticle delivery, Engelhard et al. used NCI-H2122 alongside medulloblastoma and glioblastoma cell lines to test etoposide-bound magnetic nanoparticles (Etop-MNPs) designed for remote targeting of cancer cells disseminated within cerebrospinal fluid pathways. [36] These two-part magnetic gold-iron alloy nanoparticles, coated with biotinylated etoposide, were moved at a distance by surface-walking in response to a rotating permanent magnet, and NCI-H2122 proved even more susceptible to their killing effect than the medulloblastoma line D283. NCI-H2122 served as the NSCLC representative in this proof-of-concept in vitro study.

Research into bacterial extracellular vesicle-mediated siRNA delivery used NCI-H2122 to evaluate engineered vesicles targeting SLC7A11, a cystine transporter associated with ferroptosis resistance. Knockdown of SLC7A11 in NCI-H2122 and NCI-H647 cells impaired proliferation, migration, and invasion, and lung-cell-targeted bacterial extracellular vesicles carrying SLC7A11 siRNA impaired tumorigenesis while activating ferroptosis pathways in vivo. [37] These studies demonstrate the versatility of NCI-H2122 as a test platform for innovative nucleic acid delivery technologies. Additionally, a survey of coding-region microsatellite sites in lung, breast, ovarian, and colorectal cancers found no such mutations in the lung cancer panel that included NCI-H2122, [38] and RB-family protein expression studies detected full-length RB, RBL1/p107, and RBL2/p130 species in the non-SCLC panel, indicating that in NCI-H2122 the RB/p16 pathway is disrupted through CDKN2A loss rather than through mutation of RB itself. [39]

Conclusion

NCI-H2122 stands as one of the most comprehensively characterised and widely deployed NSCLC cell lines in cancer research. Its homozygous KRAS G12C mutation, compound TP53 alterations, CDKN2A/B, STK11, and KEAP1 co-alterations, microsatellite stability, and integration into global genomic, proteomic, and pharmacological atlases make it an exceptional model for studying oncogenic RAS signalling, targeted therapy combinations, DNA damage response, and novel drug delivery. From foundational studies on cPLA2 induction by oncogenic RAS [23] to the most recent investigations of KRAS-G12C inhibitor combinations for brain metastases, [7] NCI-H2122 has consistently enabled high-impact translational discoveries. Whether your research focuses on KRAS-targeted therapeutics, combination oncology strategies, pan-cancer biomarker discovery, or innovative delivery platforms, NCI-H2122 provides the validated, well-annotated foundation your studies require. Visit cytion.com to purchase NCI-H2122 cells or to enquire about specifications, availability, and custom support for your research programme.

Key Publications

1. Phelps RM, Johnson BE, Ihde DC (1996) NCI-Navy Medical Oncology Branch cell line data base. Journal of cellular biochemistry. Supplement. PMID: 8806092
2. Mulshine JL, Ujhazy P, Antman M (2020) From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. Journal of cellular biochemistry. PMID: 31803961
3. Mitsudomi T, Steinberg SM, Nau MM (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. PMID: 1311061
4. Iwakawa R, Kohno T, Enari M, Kiyono T, Yokota J (2010) Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer science. PMID: 20557307
5. Grigorova M, Lyman RC, Caldas C (2005) Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer genetics and cytogenetics. PMID: 16157194
6. Garnis C, Lockwood WW, Vucic E (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. International journal of cancer. PMID: 16187286
7. Migliarese C, Sadeh Y, Torrini C (2025) Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A. Acta neuropathologica communications. PMID: 40317086
8. Liu Y, Marks K, Cowley GS (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer discovery. PMID: 23715154
9. Weiss-Sadan T, Ge M, Hayashi M (2023) NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer. Cell metabolism. PMID: 36841242
10. Dutil J, Chen Z, Monteiro AN (2019) An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. Cancer research. PMID: 30894373
11. Barretina J, Caponigro G, Stransky N (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. PMID: 22460905
12. Ghandi M, Huang FW, Jané-Valbuena J (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID: 31068700
13. Nusinow DP, Szpyt J, Ghandi M (2020) Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. PMID: 31978347
14. Gonçalves E, Poulos RC, Cai Z (2022) Pan-cancer proteomic map of 949 human cell lines. Cancer cell. PMID: 35839778
15. Cowley GS, Weir BA, Vazquez F (2014) Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific data. PMID: 25984343
16. Yu M, Selvaraj SK, Liang-Chu MM (2015) A resource for cell line authentication, annotation and quality control. Nature. PMID: 25877200
17. Scholtalbers J, Boegel S, Bukur T (2015) TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome medicine. PMID: 26589293
18. Jameson NM, Kim D, Lee C (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRAS-G12C Inhibitors in Preclinical Models. Cancer research communications. PMID: 39807828
19. Zhou C, Liu Y, Liu H (2025) WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRAS-mutant lung cancer. Cell death & disease. PMID: 40885709
20. Yoshimura A, Horinaka M, Yaoi T (2024) Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer. PMID: 38822146
21. Patel HV, Smith AE, Chan S (2026) The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition. Cancer research. PMID: 41661652
22. Calvo E, Chen VJ, Marshall M (2014) Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Investigational new drugs. PMID: 24942404
23. Heasley LE, Thaler S, Nicks M (1997) Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. The Journal of biological chemistry. PMID: 9169405
24. Balbin OA, Prensner JR, Sahu A (2013) Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nature communications. PMID: 24135919
25. Rikova K, Guo A, Zeng Q (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. PMID: 18083107
26. Wang K, Zhang FL, Jia W (2021) Glutathione S-transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non-small cell lung cancer cells, via the JAK/STAT3 signaling pathway. Molecular medicine reports. PMID: 33236161
27. Wang Z, Xu H, Zhang J (2020) Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT/MMP-2/VEGF pathway. Basic & clinical pharmacology & toxicology. PMID: 31314153
28. Girard L, Zöchbauer-Müller S, Virmani AK (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer research. PMID: 10987304
29. Blanco R, Iwakawa R, Tang M (2009) A gene-alteration profile of human lung cancer cell lines. Human mutation. PMID: 19472407
30. Bignell GR, Greenman CD, Davies H (2010) Signatures of mutation and selection in the cancer genome. Nature. PMID: 20164919
31. Li J, Zhao W, Akbani R (2017) Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer cell. PMID: 28196595
32. Klijn C, Durinck S, Stawiski EW (2015) A comprehensive transcriptional portrait of human cancer cell lines. Nature biotechnology. PMID: 25485619
33. Iorio F, Knijnenburg TA, Vis DJ (2016) A Landscape of Pharmacogenomic Interactions in Cancer. Cell. PMID: 27397505
34. McMillan EA, Ryu MJ, Diep CH (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell. PMID: 29681454
35. Yada A, Yazawa M, Ishida S (2008) A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Annals of oncology. PMID: 18304965
36. Engelhard HH, Willis AJ, Hussain SI (2020) Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways. Frontiers in neurology. PMID: 33329349
37. Wan XD, Zhou XL, Liu JL, Xu H (2025) Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of non-small cell lung cancer. Bioengineering & translational medicine. PMID: 41030277
38. Forgacs E, Wren JD, Kamibayashi C (2001) Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. Oncogene. PMID: 11314036
39. Modi S, Kubo A, Oie H (2000) Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene. PMID: 11030152